The emerging role of complement inhibitors in transplantation

Kidney International

Volumn 88, Issue 5, 2015, Pages 967-973

  Frémeaux Bacchi, Véronique ^a,b   Legendre, Christophe M ^c,d  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d Universite de Paris Diderot   (France)

Author keywords

Acute rejection; Complement; Delayed graft function; Hemolytic uremic syndrome

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT INHIBITOR; ECULIZUMAB; IMMUNOGLOBULIN; COMPLEMENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ANGIONEUROTIC EDEMA; ANTIBODY MEDIATED REJECTION; ANTIPHOSPHOLIPID SYNDROME; BLOOD GROUP ABO INCOMPATIBILITY; C3 GLOMERULOPATHY; CHRONIC GRAFT REJECTION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT DISORDER; COMPLEMENT INHIBITION; DELAYED GRAFT FUNCTION; GLOMERULOPATHY; GRAFT FAILURE; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; HISTOCOMPATIBILITY; IMMUNOLOGY; METABOLISM; REPERFUSION INJURY;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; HUMANS; KIDNEY TRANSPLANTATION; REPERFUSION INJURY; TRANSPLANTATION IMMUNOLOGY;

EID: 84947611518     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.253     Document Type: Short Survey

References (32)

1. Ricklin D, Hajishengallis G, Yang K et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-797.
2. Loupy A, Lefaucheur C, Vernerey D et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226.
3. Mathern DR, Heeger PS. Molecules great and small: the complement system. Clin J Am Soc Nephrol 2015 (e-pub ahead of print).
4. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066.
5. Thomas KA, Valenzuela NM, Gjertson D et al. An anti-C1s monoclonal, TNT003, inhibits complement activation induced by antibodies against HLA. Am J Transplant 2015; 15: 2037-2049.
6. Sacks SH, Zhou W. The role of complement in the early immune response to transplantation. Nat Rev Immunol 2012; 12: 431-442.
7. Le Quintrec M, Zuber J, Moulin B et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013; 13: 663-675.
8. Zand L, Lorenz EC, Cosio FG et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol 2014; 25: 1110-1117.
9. Lonze BE, Zachary AA, Magro CM et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14: 459-465.
10. King KE, Warren DS, Samaniego-Picota M et al. Antibody, complement and accommodation in ABO-incompatible transplants. Curr Opin Immunol 2004; 16: 545-549.
11. Cravedi P, Heeger PS. Complement as a multifaceted modulator of kidney transplant injury. J Clin Invest 2014; 124: 2348-2354.
12. Patel R, Mickey MR, Terasaki PI. Serotyping for homotransplantation. XVI. Analysis of kidney transplants from unrelated donors. N Engl J Med 1968; 279: 501-506.
13. Feucht HE, Felber E, Gokel MJ et al. Vascular deposition of complementsplit products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464-470.
14. Sapir-Pichhadze R, Curran SP, John R et al. A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection. Kidney Int 2015; 87: 182-194.
15. Wahrmann M, Dohler B, Ruhenstroth A et al. Genotypic diversity of complement component C4 does not predict kidney transplant outcome. J Am Soc Nephrol 2011; 22: 367-376.
16. Sicard A, Ducreux S, Rabeyrin M et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol 2014; 26: 457-467.
17. Loupy A, Lefaucheur C, Vernerey D et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol 2014; 25: 2267-2277.
18. Tillou X, Poirier N, Le Bas-Bernardet S et al. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 2010; 78: 152-159.
19. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169-2181.
20. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8: 554-562.
21. Zuber J, Fakhouri F, Roumenina LT et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643-657.
22. Stegall MD, Diwan T, Raghavaiah S et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413.
23. Cornell LD, Schinstock CA, Gandhi MJ et al. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant 2015; 15: 1293-1302.
24. Zuber J, Le Quintrec M, Krid S et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12: 3337-3354.
25. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748-756.
26. Canaud G, Kamar N, Anglicheau D et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 2013; 13: 2179-2185.
27. Zhang Y, Nester CM, Holanda DG et al. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol 2013; 24: 1820-1829.
28. Vo AA, Zeevi A, Choi J et al. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation 2015; 99: 299-308.
29. Ricklin D, Lambris JD. Progress and trends in complement therapeutics. Adv Exp Med Biol 2013; 735: 1-22.
30. Xiao H, Dairaghi DJ, Powers JP et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 2014; 25: 225-231.
31. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 2013; 190: 3831-3838.
32. Risitano AM, Ricklin D, Huang Y et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014; 123: 2094-2101.